Target Name: OR2T1
NCBI ID: G26696
Review Report on OR2T1 Target / Biomarker Content of Review Report on OR2T1 Target / Biomarker
OR2T1
Other Name(s): OR1-25 | olfactory receptor family 2 subfamily T member 1 | olfactory receptor OR1-61 | olfactory receptor 1-25 | Olfactory receptor 2T1 | Olfactory receptor family 2 subfamily T member 1 | Olfactory receptor OR1-61 | OR2T1_HUMAN | Olfactory receptor 1-25

OR2T1 as A Potential Drug Target for Neurological Disorders

OR2T1 (OR1-25), a protein that is expressed in the brain, has been identified as a potential drug target (OR1-25) and a biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. OR2T1 is a transmembrane protein that is expressed in the brain and is involved in various signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established pathway that is involved in the development and maintenance of tissues, including the brain. TGF-β signaling has been implicated in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.

OR2T1 has been shown to be involved in the TGF-β pathway in various ways. For example, OR2T1 has been shown to play a role in the regulation of TGF-β signaling in the brain. Studies have shown that OR2T1 can inhibit the activity of the TGF-β receptor, which is a key component of the TGF-β pathway. This inhibition of TGF-β signaling by OR2T1 has been shown to protect against the development of neurodegeneration in various models, including mouse models of Alzheimer's disease and Parkinson's disease.

In addition to its role in TGF-β signaling, OR2T1 has also been shown to be involved in the regulation of cell survival and metabolism. Studies have shown that OR2T1 can promote the survival of brain cells under conditions of neurodegeneration, and that this survival is dependent on the levels of the protein. Additionally, OR2T1 has been shown to be involved in the regulation of metabolism, as it has been shown to play a role in the upregulation of genes involved in metabolism.

Given the involvement of OR2T1 in the TGF-β pathway and its role in the regulation of cell survival and metabolism, it is a potential drug target for the treatment of neurological disorders. Studies have shown that inhibiting the activity of OR2T1 using small interfering RNA (siRNA) has been effective in treating various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. Additionally, OR2T1 has been shown to be a potential biomarker for the diagnosis of these disorders, as the levels of OR2T1 have been shown to be decreased in the brains of individuals with these disorders.

In conclusion, OR2T1 is a protein that is involved in various signaling pathways, including the TGF-β pathway. Its involvement in these pathways makes it a potential drug target for the treatment of neurological disorders. Studies have shown that inhibiting the activity of OR2T1 using small interfering RNA has been effective in treating various neurological disorders, and that it has the potential to serve as a biomarker for the diagnosis of these disorders. Further research is needed to fully understand the role of OR2T1 in the treatment of neurological disorders and to develop safe and effective drugs that target OR2T1.

Protein Name: Olfactory Receptor Family 2 Subfamily T Member 1

Functions: Odorant receptor

The "OR2T1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2T1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2